The intellectual lineage of the approach is worth emphasizing. The symbolic notation descends from the system dynamics tradition initiated by Jay Forrester at MIT, but its biological form was shaped decisively by Howard T. Odum, who spent decades developing a rigorous algebraic framework grounded in the thermodynamics of open systems. Odum’s central insight was that very different kinds of flows—solar radiation, water, biomass, money, information—could be placed on a common footing by expressing them in energy terms, allowing heterogeneous parts of a system to be compared and balanced within a single accounting scheme. In ecology this produced models of ecosystems, estuaries, and whole economies of nature that could be simulated over decades. What the present work demonstrates is that the same machinery, with an ATP-equivalent unit serving as the common currency, can be pointed at the machinery of the vertebrate immune system without any fundamental modification of the formalism.

That transfer is less trivial than it may appear. In ecological applications, the stocks are typically pools of biomass or nutrients, and the processes are feeding, respiration, and recycling. In the immune model, the stocks are populations of cells—naive and activated lymphocytes, germinal-center participants, plasma cells of varying lifespans—and the flows are proliferation, differentiation, death, and antibody secretion. The conceptual bridge is that every one of these biological processes has an energetic cost that can be expressed in the shared unit, and every regulatory interaction can be drawn as a flow of information or control. The authors are careful to distinguish real flows, which physically move matter or energy between stocks and therefore enter the balance equations, from control flows, which regulate processes but carry negligible energy of their own and are deliberately excluded from the outflow accounting of a stock. This distinction, borrowed from engineering practice, prevents the common modeling error of double-counting regulatory signals as material resources.

The choice of the antigen-specific adaptive immune response as a proof of concept is strategically astute. Humoral immunity is one of the best-characterized dynamic systems in biomedicine, with a rich experimental literature documenting germinal-center kinetics, the lifespan distributions of plasma cell subsets, and the decay of circulating antibody over years. That empirical richness matters enormously for a modeling framework in which parameters are constrained by observation rather than fitted freely. The simulator reproduces phenomena operating on strikingly different time scales simultaneously: the days-long cycles of germinal-center reaction, the monthly establishment of durable antibody-secreting populations, and the decadal slow decline of antibody titers in the absence of re-exposure. Capturing all of these within one coherent set of coupled differential equations is a demanding test, because errors in the fast dynamics propagate into the slow ones, and the model must conserve its accounting across all of them.

The thermodynamic grounding deserves particular attention because it is what separates this approach from purely phenomenological curve-fitting. Open systems thermodynamics holds that living systems maintain their organization by continuously dissipating energy gradients, and that the structure of those gradients—the sources, sinks, storage, and recycling pathways—constrains what dynamic behaviors are physically possible. By building models whose bookkeeping respects those constraints, ESL simulators inherit a form of physical plausibility: they cannot invent unlimited growth from finite resources, and they cannot sustain oscillations without an energy source. In biomedical terms, this means that a model of a lymphoid compartment cannot produce more plasma cells than the available activation events and proliferation capacity permit, a discipline that purely statistical models of cell populations often lack.

The question of spatial constraints, which the authors single out as a persistent problem in cell-population modeling, illustrates the value of treating space as a stock. Immune memory formation and plasma-cell malignancies both depend critically on where cells reside: germinal centers are physically bounded structures within lymphoid tissue, and the survival of long-lived plasma cells depends on limited niches in the bone marrow. Conventional compartment models often handle this with ad hoc carrying-capacity terms whose biological justification is unclear. In the ESL framework, units of space can be represented as a quasi-energetic stock that is consumed and released by the processes occupying it, making crowding, competition for niches, and the saturation of lymphoid architecture explicit components of the dynamics rather than afterthoughts. This is a genuinely useful formal move, and it is the kind of thing that becomes natural only when the modeling language treats extensive quantities uniformly.

The contrast drawn with network analysis and related data-driven methods should be read as complementary rather than adversarial. Network medicine has been extraordinarily successful at identifying hubs, modules, and topological vulnerabilities in molecular interaction graphs, and those findings supply exactly the biomedical knowledge from which ESL diagrams can be constructed. The two approaches operate at different levels of description: one characterizes the static wiring of a system, the other the dynamic behavior that wiring produces over time. A plausible division of labor emerges in which network methods inform which stocks and interactions belong in a diagram, while the ESL simulator tests whether the proposed structure actually generates the observed temporal patterns. Discrepancies between simulated and observed dynamics then become diagnostic, pointing to missing feedbacks or misestimated flows rather than simply degrading a fit statistic.

The emphasis on what-if exploration connects this work to a broader aspiration in medicine: the construction of disease digital twins. The idea of a patient-specific computational surrogate that can be interrogated before committing to a therapeutic intervention has gained traction across oncology and immunology, but most implementations remain either too abstract to be mechanistic or too mechanistic to be tractable. An ESL-based simulator occupies an interesting middle ground. Because its parameters are tied to empirical observation and biophysical constraints, it can in principle be personalized—adjusted to reflect a particular patient’s measured cell counts, antibody levels, or tissue capacities—without abandoning its mechanistic structure. Because it is dynamic, it can be run forward under hypothetical interventions, asking how a proposed drug schedule, cell-depletion regimen, or antigen re-exposure would alter the trajectory of the system.

The application to lymphoid malignancies and autoimmune diseases named by the authors is well chosen, because both classes of pathology are paradigmatically systemic. Autoimmune disease involves feedback loops in which tissue damage releases antigens that further stimulate the immune response, creating self-amplifying cycles that no single molecular target fully explains. Lymphoid malignancies arise from the same cell populations the model represents—germinal-center B cells and their descendants—and their clinical behavior, including dormancy, relapse, and transformation, exhibits the regime shifts and patient-to-patient variability that linear models handle poorly. A simulator that captures the normal dynamics of these compartments provides a baseline against which pathological rewiring can be expressed as specific, testable modifications to the diagram: a broken feedback, an altered carrying capacity, a redirected flow.

There are, of course, challenges that the proof of concept does not yet resolve. Selecting the right state variables requires judgment, and different modelers might draw different diagrams for the same biological system, with consequences that are not always easy to anticipate. Parameter estimation for processes operating across decades, such as plasma-cell longevity, depends on sparse and indirect measurements. Validation of what-if predictions ultimately requires experiments or clinical observations that the model itself cannot replace. And the translation from a symbolic diagram to a system of coupled differential equations, while systematic, still involves choices about functional forms for interactions that can shape simulated behavior. These are the ordinary difficulties of mechanistic modeling, but they are worth stating plainly, because the framework’s value will be judged by how well its predictions survive contact with data.

What the work ultimately offers is a demonstration that a modeling language developed for ecological complexity, with roots stretching back to mid-twentieth-century systems thinking, can be brought to bear on one of the most intricate dynamic systems in human biology without losing its rigor. The immune system, with its layered feedbacks, its memory, and its capacity for self-organization across time scales, is a demanding test case, and the successful reproduction of its hallmark behaviors suggests that the formalism has genuine reach. If subsequent studies extend the approach to pathological variants of the same system, and if patient-specific parameterization proves feasible in practice, the vision of computational tools that support hypothesis testing for individualized therapeutic strategies will have moved from aspiration toward method. The deeper contribution may be conceptual: a reminder that the dynamics of disease are properties of organized systems, and that a language designed to express organization—stocks, flows, feedback, and the thermodynamic constraints that bind them—may be exactly what biomedicine needs to reason clearly about complexity.

Subject of Research: Thermodynamics-based energy systems modeling of the adaptive immune response

Article Title: Addressing biomedical complexity using the energy systems language

Article References: Surra, F., Gonella, F., Conte, L., & Romano, A. (2026). Addressing biomedical complexity using the energy systems language. Frontiers in Systems Biology, 6, Article 1903662. https://doi.org/10.3389/fsysb.2026.1903662

Image Credits: AI Generated

DOI: 10.3389/fsysb.2026.1903662

Keywords: energy systems language, systems biology, immune response, plasma cells, antibodies, thermodynamics, computational modeling, digital twin, multiple myeloma, autoimmune disease, bone marrow niche, feedback loops

The research team, led by Gersende Caron and Thierry Fest of the University of Rennes, established a laboratory system that coaxes purified B cells from human tonsils down the full path to antibody secretion. The culture proceeds in two stages. First, B cells sit on stromal cells engineered to display CD40L, bathed in a cocktail of the cytokines BAFF, IL-2, IL-4, and IL-21, which mimics the help that T cells provide inside germinal centers. After six days of proliferation, the cells are transferred onto a different feeder layer with IL-6, pushing survivors toward terminal differentiation. Flow cytometry confirmed that the system genuinely reproduces physiology, generating CD20-low, CD38-high, CD138-positive cells with the hallmarks of mature plasma cells.

To watch the transition unfold molecule by molecule, the researchers performed single-cell RNA sequencing at days zero, six, eight, and ten, profiling 17,220 cells from three donors. Unsupervised clustering resolved twelve transcriptionally distinct populations spanning naive B cells, germinal center states, proliferating activated cells, and antibody-secreting cells. When the team reconstructed developmental trajectories with pseudotime analysis, a striking pattern emerged: day eight marked a fork in the road. One branch led to plasma cells, a second to memory B cells, and a third to a germinal-center-like state. Crucially, the cells sitting at the branch point had not yet turned on the canonical plasma cell regulators PRDM1 and IRF4, meaning they were transcriptionally primed for the secretory fate before committing to it.

To capture the coordinated gene programs behind this priming, the investigators applied high-dimensional weighted gene co-expression network analysis, which grouped thousands of genes into thirteen modules based on their correlated expression across single cells. One module, designated M3, stood out. It sat between germinal-center and mature plasma cell modules in the network, overlapped heavily with genes defining the plasma cell trajectory, and was rich in targets of XBP1, the master transcription factor of the unfolded protein response that drives endoplasmic reticulum expansion. Seven of its ten hub genes matched the pseudotime-defined plasma cell fate, and one of the most highly expressed members of the module was CAV1, the gene encoding Caveolin-1.

Chromatin immunoprecipitation experiments confirmed that this was no coincidence. XBP1, the spliced form activated during ER stress, bound directly to a site roughly 450 base pairs upstream of the CAV1 transcription start site in differentiating cells, with enrichment comparable to that seen at HSPA5, a well-established XBP1 target. CAV1 transcripts, undetectable in resting B cells, rose sharply along the plasma cell trajectory, reaching peak levels in both proliferating plasmablasts and mature plasma cells. Independent single-cell datasets from memory-to-plasma-cell differentiation reproduced the same induction, and surveys of public atlases showed CAV1 expression in tonsillar plasmablasts and bone marrow plasma cells, even though it is essentially absent from immune cells elsewhere.

The story took an intriguing turn when the team examined protein isoforms. Western blotting revealed that in vitro-generated plasma cells exclusively expressed the beta isoform of Caveolin-1, a roughly 19-kilodalton splice variant lacking the tyrosine-14 phosphorylation site that features prominently in classical caveolin signaling. Ex vivo, plasmablasts expressed only the beta isoform, while mature bone marrow plasma cells added low levels of the alpha transcript. Strikingly, mouse plasma cells show no Cav1 expression at all, making this a human-specific feature of antibody-secreting cells. Immunofluorescence microscopy showed the protein sitting predominantly inside the cell, co-localizing with the Golgi marker GM130 rather than with the endoplasmic reticulum, mitochondria, or lysosomes, and neither activated B cells nor plasmablasts expressed the Cavin proteins and EHD2 needed to build true caveolae. Human plasma cells, in other words, deploy a non-caveolar Caveolin.

Single-cell and bulk RNA-seq data revealed that CAV1 expression in B cells is actually biphasic. Within twelve to twenty-four hours of activation, a transient pulse of CAV1 appears, driven primarily by CD40L signaling through the transcription factor Ikaros. When the researchers degraded Ikaros pharmacologically with the molecular glue Mezigdomide, the early pulse collapsed. This initial wave is functionally silent as far as the team could detect: silencing CAV1 did not alter BCR-proximal phosphorylation cascades, STAT and AKT signaling, T cell-B cell conjugate formation, proliferation, or plasmablast differentiation. The second wave, sustained and XBP1-dependent, accompanies plasma cell commitment and persists through terminal differentiation.

Functional perturbation showed that Caveolin-1β is a fine-tuner rather than a master switch. Silencing CAV1 in pre-plasmablasts slightly but reproducibly increased the yield of CD138-positive plasma cells without changing total immunoglobulin secretion. Transcriptomic profiling of the knockdown cells revealed only modest shifts, but among them were meaningful signals: integrin alpha-6, encoded by ITGA6 and implicated in retaining plasma cells within the bone marrow niche, went up, while ID3, whose repression marks plasma cell commitment, went down. Co-immunoprecipitation detected an association between Cav-1 and the autophagy protein Atg5, though autophagic flux assays detected no functional change, and XBP1s levels were unaffected by the knockdown even under drug-induced ER stress.

The most revealing results came from proteomics. Affinity purification followed by mass spectrometry in a multiple myeloma cell line identified 348 proteins physically associated with Cav-1β, enriched for components of the endoplasmic reticulum, Golgi, mitochondria, lysosomes, and secretory machinery. Among the interactors were twenty-eight proteins encoded by XBP1 target genes from module M3, including the oligosaccharyltransferase complex and the SEC61 translocon, placing Cav-1β squarely within the secretory remodeling program. Even more striking was the overlap with nutrient-sensing machinery: the RAGulator complex, Rag GTPases, V-ATPase subunits, the amino acid transporter CD98/LAT1, and the XBP1-regulated chaperone HYOU1, which helps activate mTORC1. Cells expressing CAV1 were indeed enriched for mTORC1 transcriptional signatures, yet the interactions did not translate into regulation. Depleting Cav-1 left acute amino-acid-induced mTORC1 activation, RAGulator assembly, and RAPTOR recruitment intact, arguing that Cav-1β functions as a spatial scaffold rather than a signaling catalyst.

The authors propose a model in which Cav-1β acts as a structural organizer of the expanding plasma cell cytoplasm, tethering ER, Golgi, lysosomal, and metabolic networks into a coordinated architecture that balances secretory output with nutrient sensing. Whether this scaffolding matters for the long-term survival of the bone marrow plasma cells that maintain antibody immunity for decades remains an open question, as does its relevance to multiple myeloma and autoimmune diseases driven by pathological antibody-secreting cells. The mouse-human divergence is itself a caution: the tools of murine immunology may simply not see this layer of plasma cell biology. For now, the study adds a previously hidden membrane scaffold to the blueprint of the human antibody factory and demonstrates, once again, how single-cell maps can expose molecular players invisible to bulk approaches.

Subject of Research: Single-cell analysis of human B cell differentiation identifying a commitment checkpoint and XBP1-driven Caveolin-1β expression associated with mTORC1 machinery in plasma cells

Article Title: Single-cell mapping of human plasma cell fate reveals a commitment checkpoint and Cav-1β expression associated with mTORC1 machinery

Article References: Caron, G., Desmots, F., Chabaud, M., Lemarié, M., Olivier, V., Chatonnet, F., Nonn, C., Jadeau, C., Léonard, S., Monvoisin, C., Santamaria, K., Blouin, C. M., Attaf, N., Gharsalli, T., Milpied, P., Lamaze, C., Pangault, C., Haas, M., & Fest, T. (2026). Single-cell mapping of human plasma cell fate reveals a commitment checkpoint and Cav-1β expression associated with mTORC1 machinery. iScience, 29(11), Article 117865. https://doi.org/10.1016/j.isci.2026.117865

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117865

Keywords: plasma cells, B cell differentiation, Caveolin-1, XBP1, mTORC1, single-cell RNA sequencing, unfolded protein response, endoplasmic reticulum, germinal center, RAGulator, antibody secretion, proteomics

The research, conducted at the University Teaching Hospital and the Cancer Diseases Hospital in Lusaka, recruited 30 patients with multiple myeloma and 42 age- and sex-matched healthy controls. The investigators, led by Kapina Mwampembwa and colleagues, designed the study as a cross-sectional analytical comparison, meaning they measured neutrophil function at a single point in time across both groups and then examined how strongly the measurements discriminated between patients and controls. Crucially, the cohort included both newly diagnosed and relapsed patients, allowing the team to capture immune dysfunction across the disease course rather than in a single, potentially unrepresentative stage.

Multiple myeloma arises when plasma cells, the antibody factories of the bone marrow, proliferate uncontrollably and crowd out healthy blood-forming tissue. The disease is already known to suppress immunity in several ways: malignant plasma cells displace normal immune precursors, produce abnormal antibodies that fail to neutralize pathogens, and alter the bone marrow microenvironment in ways that impair immune cell development. Infections remain one of the leading causes of illness and death in myeloma patients, particularly during early treatment when disease-related immune suppression overlaps with the effects of chemotherapy. Whether neutrophils themselves contribute meaningfully to this infection risk has been difficult to establish, because standard blood counts often appear reassuringly normal.

To test neutrophil function directly, the researchers drew four milliliters of venous blood from each participant into tubes containing EDTA, an anticoagulant that preserves cells for laboratory analysis. Neutrophils were then isolated from the whole blood using a density-gradient medium called Polymorphprep, which separates blood cells into distinct layers based on their density, allowing a purified neutrophil fraction to be collected. This step is critical because functional assays are only interpretable if the cells being tested are a well-defined population rather than a mixture of different white blood cells.

The team then ran two complementary assays, both read by flow cytometry, a technique that passes individual cells through a laser and measures fluorescent signals emitted by each one. The first test measured phagocytosis, the process by which neutrophils engulf bacteria. Researchers incubated the isolated neutrophils with fluorescently labeled bacterial particles and used the flow cytometer to determine what proportion of neutrophils had successfully swallowed the particles, indicated by fluorescence inside the cells. The second test measured the oxidative burst, the explosive production of reactive oxygen species that neutrophils deploy to kill the microbes they have engulfed. For this, the cells were loaded with a fluorescent probe, 2′,7′-dichlorodihydrofluorescein diacetate, which becomes fluorescent when oxidized by the reactive chemicals generated during the respiratory burst. A brighter signal means more active bacterial killing machinery.

The results were striking. Neutrophils from myeloma patients engulfed bacterial particles at a rate of 45.0 percent on average, compared with 75.9 percent in healthy controls, a difference that was highly statistically significant with a P value below 0.001. Oxidative burst showed a nearly identical pattern: only 44.7 percent of patient neutrophils produced reactive oxygen species at detectable levels, versus 74.9 percent of control neutrophils, again with P below 0.001. In practical terms, roughly half of the functional capacity of these innate immune cells was missing in the patient group, even though many of these patients had absolute neutrophil counts within the range that clinicians would normally consider adequate.

To quantify how strongly these functional defects were tied to myeloma itself, the researchers turned to logistic regression, a statistical method that estimates the odds of an outcome, in this case being a myeloma patient, as a function of one or more predictor variables. The associations were extraordinary in magnitude. Patients with impaired oxidative burst had odds of being in the myeloma group more than five thousand times higher than those with normal burst activity, with an odds ratio of 5097.6 and P below 0.001. Phagocytic dysfunction produced an even larger odds ratio of 7272.7, also highly significant. These figures should be interpreted with caution, because odds ratios of this size in a modestly sized cross-sectional study reflect near-perfect separation between groups rather than a literal risk multiplier, but they underscore just how consistently the functional defects tracked with the disease.

Equally informative was what did not predict dysfunction. Age, sex, total white blood cell count, and absolute neutrophil count all failed to show significant associations with either phagocytic capacity or oxidative burst in the regression models. This finding cuts against the conventional reliance on the absolute neutrophil count as the primary marker of innate immune competence in cancer patients. A patient whose blood report shows a normal neutrophil number may nonetheless harbor neutrophils that are functionally crippled, unable to engulf bacteria or generate the reactive chemicals needed to kill them. The study’s authors argue that this qualitative impairment, invisible on routine full blood counts, may help explain why myeloma patients suffer serious infections even when they are not classically neutropenic.

The mechanisms behind the dysfunction remain to be fully worked out, but several plausible candidates follow from myeloma biology. Malignant plasma cells secrete cytokines and other signaling molecules that can suppress myeloid cell development in the bone marrow, potentially releasing neutrophils that are immature or intrinsically defective. The abnormal antibodies produced by the tumor can form immune complexes that pre-activate or exhaust neutrophils in the circulation. In addition, the chronic inflammatory state that accompanies advanced cancer is known to generate a population of suppressive, functionally impaired granulocytes in both human cancers and animal models. The current study did not dissect these pathways, but by demonstrating that the defect is real, reproducible, and measurable with standard flow cytometry tools, it establishes the foundation for such mechanistic work.

The clinical implications are potentially significant. If neutrophil dysfunction can be monitored over time, clinicians might identify patients at heightened infection risk before an infection occurs, guiding decisions about prophylactic antibiotics, immunoglobulin replacement, or the intensity of chemotherapy regimens. Functional assays of the kind used here require only a small blood sample, a density gradient, and a flow cytometer, making them feasible in regional hospitals in high-burden settings, although they are more technically demanding than a routine blood count. The study also carries broader relevance beyond myeloma, since qualitative neutrophil defects are increasingly recognized in other hematologic malignancies and in critically ill patients. For now, the message from Lusaka is clear: in multiple myeloma, the immune system’s most abundant soldiers may be present in full number yet fighting at half strength, and only by testing what they can do, rather than how many there are, can that hidden vulnerability be seen.

Subject of Research: Neutrophil functional impairment in patients with multiple myeloma

Article Title: Functional characterization of neutrophils in patients with multiple myeloma

Article References: Mwampembwa, K., Mweni, E., Mwape, H., Daka, R., Nzobokela, J., Chisanga, C., & Munsaka, S. (2026). Functional characterization of neutrophils in patients with multiple myeloma. PLOS One, 21(10), e0360063. https://doi.org/10.1371/journal.pone.0360063

Image Credits: AI Generated

DOI: 10.1371/journal.pone.0360063

Keywords: multiple myeloma, neutrophils, phagocytosis, reactive oxygen species, flow cytometry, innate immunity, immune dysfunction, infection risk, logistic regression, Zambia, hematologic cancer, plasma cells

IgG4-related disease is an enigmatic condition in which immune cells called IgG4-positive plasma cells infiltrate tissues throughout the body, triggering chronic inflammation and, ultimately, the formation of dense fibrous scar tissue. This multiorgan fibrosis can strike nearly any part of the anatomy: the salivary and lacrimal glands, the pancreas, the kidneys, the lungs, the thyroid, and, in a substantial minority of patients, the skin. Diagnosis is notoriously tricky, resting on a combination of clinical examination, elevated serum IgG4 concentrations, and characteristic histopathological findings on biopsy. The 2019 classification criteria developed by the American College of Rheumatology and the European League Against Rheumatism have helped standardize diagnosis, but the underlying biology of the disease remains incompletely characterized, leaving clinicians without a targeted therapy designed specifically for it.

That gap in understanding is precisely where dupilumab enters the picture. Although the complete pathophysiology of IgG4-related disease has not been fully mapped, researchers have identified two molecular culprits that make it an attractive target. Interleukin-4 is the cytokine that drives immunoglobulin class switching, coaxing B cells into producing the IgG4 antibodies that give the disease its name. Interleukin-13, its close molecular relative, is a well-established mediator of fibrosis, the scarring process that can permanently damage organs in advanced disease. Dupilumab works by binding the interleukin-4 receptor alpha subunit, a shared signaling gateway that both interleukin-4 and interleukin-13 require to transmit their instructions into cells. Blocking that gateway simultaneously silences two processes central to the disease: the production of IgG4 antibodies and the fibrotic remodeling of tissue.

The drug is no stranger to dermatology clinics. Approved for moderate-to-severe atopic dermatitis, dupilumab has demonstrated favorable safety and sustained efficacy in open-label studies extending up to three years, and it has since been deployed against a growing list of inflammatory skin and airway conditions. Its mechanism, however, makes it uniquely suited to IgG4-related disease in theory, because no other approved therapy hits both the class-switching and fibrotic arms of the pathology at once. Traditional immunosuppressants blunt the immune system broadly, while rituximab, the most effective agent currently available, depletes B cells entirely and carries its own risks and limitations.

The Ohio State team, led by Diana Hallak and colleagues in the Department of Dermatology, presents two cases that illustrate both the promise and the complexity of this approach. The first patient, a 54-year-old woman with a history of Hashimoto’s thyroiditis, presented with a generalized, intensely itchy papular rash. Biopsy findings and elevated serum IgG4 levels confirmed a diagnosis of IgG4-related disease. She initially failed treatment with mycophenolate mofetil, an immunosuppressant commonly used as a steroid-sparing agent. When dupilumab was started, her rash improved substantially, a striking response for a patient whose disease had resisted conventional therapy. Yet her course was not straightforward: she later experienced recurrent flares despite continuing the drug, requiring further adjustments to her medication regimen.

The second patient tells a more uniformly triumphant story. A 42-year-old woman had IgG4-related disease affecting both her lacrimal glands, the structures that produce tears, and her skin. After multiple treatment failures, she began dupilumab and achieved sustained control of her disease. For a condition that can progressively destroy glandular tissue and disfigure the periorbital region, durable remission on a well-tolerated biologic represents a meaningful clinical win. The contrast between the two patients, one with lasting benefit and one with breakthrough flares, underscores an important caveat: dupilumab may not produce uniform or permanent responses, and some patients may need combination or sequential strategies.

To place these two cases in context, the authors conducted a systematic review of the published literature, identifying thirteen additional cases of IgG4-related disease treated with dupilumab. The pattern across those reports is striking. In all but one of the published case reports, dupilumab consistently improved clinical symptoms and reduced serum IgG4 levels, the laboratory marker most closely watched by clinicians managing the disease. Reported successes span a wide range of manifestations, including dacryoadenitis and sialoadenitis, steroid-dependent disease complicated by asthma, aspirin-exacerbated respiratory disease overlapping with IgG4-related disease, and the adult-onset asthma and periocular xanthogranuloma syndrome that overlaps with IgG4-related pathology. In at least one reported case, dupilumab monotherapy was sufficient to induce remission of IgG4-related dacryoadenitis and sialoadenitis, suggesting the drug may work even without additional immunosuppression in some patients.

The immunological rationale behind these observations runs deeper than the two cytokines alone. Studies of patients with IgG4-related disease have revealed a characteristic skewing of the T cell compartment toward type 2 helper responses, with expansions of circulating follicular helper 2 T cells, a specialized subset that supports B cell antibody production. The numbers of these cells correlate with serum IgG4 levels, interleukin-4 concentrations, and plasmablast counts, the short-lived antibody-secreting cells that many researchers consider a more dynamic biomarker of disease activity than serum IgG4 itself. In other words, the type 2 immune axis that dupilumab shuts down is not a peripheral player in IgG4-related disease; it appears to be the engine driving the entire process. Blocking the interleukin-4 receptor is therefore a mechanistically precise intervention, not a blunt instrument.

Still, the evidence base remains thin, and the authors are careful about what their findings can and cannot support. Every data point in the review comes from individual case reports and small case series, study designs that are vulnerable to publication bias, since dramatic successes are far more likely to be written up than failures. There have been no randomized controlled trials of dupilumab in IgG4-related disease, no standardized dosing regimens, and no long-term safety data specific to this population. The first patient’s breakthrough flares are a reminder that initial response does not guarantee durable remission. The existing comparator, rituximab, has been evaluated in systematic reviews and meta-analyses showing efficacy both as induction and maintenance therapy, so any future role for dupilumab will need to be defined relative to that benchmark, whether as an alternative for patients who fail or cannot tolerate rituximab, or as part of a steroid-sparing strategy.

What the new report does provide is a clear signal worth testing. Fifteen patients across the literature and the new cases, most of them with disease that had defeated multiple prior therapies, overwhelmingly improved on dupilumab, with reductions in both symptoms and serum IgG4. The authors conclude that dupilumab appears efficacious in recalcitrant IgG4-related disease and emphasize that these encouraging preliminary findings underscore the need for formal clinical trials to optimize dosing regimens and evaluate long-term efficacy and safety. For patients with a disease that can silently scar organs and for whom options have long been limited to broad immunosuppression, the prospect of a targeted, well-tolerated therapy that attacks both the antibody production and the fibrosis at the heart of the condition is a reason for genuine optimism. The next step, a properly controlled trial, will determine whether dupilumab’s second act becomes standard of care.

Subject of Research: Dupilumab therapy for treatment-resistant IgG4-related disease

Article Title: Dupilumab therapy for recalcitrant IgG4-related disease: case series and literature review

Article References: Hallak, D., Quadri, I., Awethe, Z., Kirven, R. M., Pettit, C., & Kaffenberger, J. (2026). Dupilumab therapy for recalcitrant IgG4-related disease: case series and literature review. Archives of Dermatological Research, 318(1), Article 425. https://doi.org/10.1007/s00403-026-04941-9

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04941-9

Keywords: IgG4-related disease, dupilumab, interleukin-4, interleukin-13, biologics, immunotherapy, fibroinflammatory disease, plasma cells, rituximab, case series, dermatology, autoimmune disease

The adaptive immune system depends on an extraordinary diversity of antigen receptors. T cells and B cells generate their receptors through a process called V(D)J recombination, in which variable, diversity, and joining gene segments are randomly stitched together, with additional nucleotide insertions and deletions at the junctions. This combinatorial and junctional diversity, together with the pairing of heavy and light chains in B cells and alpha and beta chains in T cells, allows the immune system to recognize an almost limitless range of pathogens. The composition of these repertoires reflects immune development, tissue microenvironment, antigen exposure history, and disease status, making their systematic characterization essential for understanding immune surveillance and tissue-specific immune regulation.

Previous studies of the porcine immune repertoire relied largely on bulk sequencing, which averages signals across mixed cell populations and offers limited resolution for dissecting cellular heterogeneity and lineage relationships. Although high-throughput repertoire sequencing had revealed preferential V(D)J gene usage and clonotype expansion in pigs, those studies generally lacked simultaneous transcriptomic information, meaning receptor features could not be directly linked to immune cell identity, functional state, or tissue location. The new work closes that gap by integrating single-cell RNA sequencing with paired V(D)J repertoire sequencing at single-cell resolution.

To build the atlas, the team, led by researchers from Sun Yat-Sen University, the Harbin Veterinary Research Institute, and Beijing BestopCell, sampled three clinically healthy, 14-day-old male DLY crossbred piglets weighing approximately 4 kilograms. The animals were screened by RT-qPCR for major swine pathogens, including porcine epidemic diarrhea virus, transmissible gastroenteritis virus, porcine deltacoronavirus, rotavirus, porcine reproductive and respiratory syndrome virus, and African swine fever virus, and all tests were negative. None of the piglets had been vaccinated, ensuring that the recorded immune landscape reflected a true physiological baseline rather than an antigen-driven response.

The researchers collected eleven immune-associated tissues spanning lymphoid, mucosal, and circulatory compartments: peripheral blood, spleen, thymus, tonsil, lung, bone marrow, intestinal lymph node, bronchial lymph node, Peyer’s patch, and the mucous membranes of the ileum and jejunum. After careful tissue dissociation, debris removal, and quality control filtering that eliminated 22,141 low-quality cells, a total of 71,731 cells were retained for analysis. Sequencing was performed on an MGI DNBSEQ-T7 platform, and the data were processed with the Seurat and scRepertoire frameworks against the Sscrofa11.1 reference genome.

The cellular inventory revealed the expected cast of immune players: T cells, B cells, natural killer cells, plasma cells, monocytes, and neutrophils, alongside structural endothelial, epithelial, and fibroblast populations. Cell-type identities were anchored to canonical markers, with B cells expressing CD19, MS4A1, and CD79A; T cells expressing CD3D, CD3E, and CD3G; and plasma cells marked by MZB1 and CD38. Reclustering resolved five major B-cell subpopulations, including naive, memory, germinal center, plasma, and cycling plasma cells, and nine T-cell subpopulations ranging from naive and memory CD4 and CD8 subsets to regulatory T cells, cycling T cells, and double-positive CD4-CD8 cells. The distribution of these subsets varied sharply by tissue: lymphoid organs were dominated by adaptive immune cells, mucosal tissues carried more epithelial and innate components, and double-positive T cells concentrated in thymic compartments, consistent with thymocyte development.

On the repertoire side, the team identified 3,275 BCR clones and 13,431 TCR clones. Both receptor classes showed strongly biased, non-random V(D)J gene usage. The five most frequent BCR V genes, including IGHV1S201 and IGHV1-1501, together accounted for 39.41 percent of total V-gene usage, while the IGHJ501 segment alone represented 44.95 percent of J-gene usage. In the TCR repertoire, segments such as TRAV15 and TRBV20-201 were preferentially enriched, alongside dominant TRBJ genes. Complementarity-determining region 3 (CDR3) lengths, the hypervariable loops that contact antigen, fell into narrow, conserved intervals: 10 to 12 and 29 to 31 amino acids for BCRs, and 12 to 14 and 26 to 28 for TCRs, with these patterns remaining stable across tissues, reflecting structural constraints on receptor generation.

Cross-tissue analyses revealed a striking asymmetry between humoral and cellular immunity. BCR clonotypes were shared far more extensively between tissues, particularly among Peyer’s patch, intestinal lymph node, ileum mucosa, and peripheral blood, whereas TCR clones showed higher tissue specificity, with the strongest sharing between peripheral blood and spleen. Because the samples came from unchallenged animals, the authors interpret this multi-organ sharing not as antigen-driven expansion but as a manifestation of intrinsic V(D)J recombination bias, in which certain gene combinations and CDR3 lengths are preferentially generated, producing ‘public-like’ clonotypes that coexist systemically. The team also notes that B cells routinely recirculate through blood and lymph, while T cells tend toward tissue residency, though their homing-receptor analysis did not show a statistically significant difference between the two lineages, leaving the mechanistic basis open.

Mapping receptor sequences back onto the single-cell transcriptomic map through matched cell barcodes linked clonal dynamics to cell state. BCRs concentrated in plasma cell and cycling plasma cell populations, and the plasma cell subset showed enriched use of IGHA and IGHG heavy chains with elevated IGHG subclass diversity, hallmarks of antibody maturation and class-switch recombination. Immunoglobulin M accounted for more than half of heavy-chain usage in each B-cell cluster, while kappa and lambda light-chain preferences differed between subsets. TCRs were concentrated in naive CD4, naive CD8, regulatory, and memory CD4 T cells, and most TCR clonotypes existed as singletons, underscoring the enormous baseline diversity maintained even without acute immune challenge.

A key technical contribution came from the pig-specific V(D)J primers designed for the study. Compared with previously published porcine repertoire datasets, the strategy detected substantially more heavy-chain V, light-chain V, and light-chain J immunoglobulin alleles, offering improved sensitivity and broader coverage of porcine antibody diversity. The authors caution that the pooled-sample design cannot assess individual variability, that cell annotations lack independent orthogonal validation, and that antigen specificity was not directly tested. Even so, the atlas stands as a foundational reference for the healthy porcine adaptive immune system, with immediate relevance for vaccine design, infectious disease research, breeding for disease resistance, and the growing use of pigs as translational models in biomedical science.

Subject of Research: Single-cell profiling of T cell and B cell receptor V(D)J immune repertoires across tissues in healthy pigs

Article Title: A single-cell profile of the porcine immune repertoire: concurrent profiling of T cell receptor and B cell receptor V(D)J sequences in health

Article References: Zhang, H., Zhang, Q., Zhang, H., Wang, P., Geng, R., Pan, R., Li, C., Shi, F., Liu, J., Wu, Y., & Cao, Y. (2026). A single-cell profile of the porcine immune repertoire: concurrent profiling of T cell receptor and B cell receptor V(D)J sequences in health. Advanced Biotechnology, 4(4), Article 38. https://doi.org/10.1007/s44307-026-00139-2

Image Credits: AI Generated

DOI: 10.1007/s44307-026-00139-2

Keywords: single-cell RNA sequencing, V(D)J recombination, immune repertoire, T cell receptor, B cell receptor, porcine immunology, CDR3, clonotype sharing, plasma cells, DLY piglets, immunoglobulin isotypes, veterinary biotechnology

The research, led by Wei Hang of Cardiff University together with colleagues at Fujian Provincial Hospital, the Fujian Center for Disease Control and Prevention and partner institutions in China, applied single-cell RNA sequencing to characterize the peripheral immune landscape associated with post-COVID pulmonary fibrosis. Rather than measuring average gene expression across bulk blood samples, single-cell transcriptomics profiles each individual cell, allowing researchers to detect shifts in the composition and functional state of rare immune subsets that would otherwise be invisible. The team integrated data from 115 samples drawn across multiple cohorts, combining publicly available acute-phase COVID-19 datasets with an in-house cohort recruited in Fujian province.

The design of the study reflects the central challenge of fibrosis research: the scar tissue itself is buried deep in the lung, inaccessible to routine sampling. The investigators therefore worked backwards from outcome. Public acute-phase datasets were stratified by an estimated fibrosis risk score, yielding a high-risk group of 50 patients and a low-risk group of 52. These were complemented by the Fujian cohort, in which 13 patients were sampled at the two-week post-discharge timepoint; seven of them had CT-confirmed pulmonary fibrosis while six did not. By comparing immune profiles across these strata, the researchers sought peripheral signatures that track with fibrotic risk even before structural damage becomes radiologically obvious.

The headline finding is a pronounced dysregulation of the B cell compartment in patients judged to be at higher fibrosis risk. Naive B cells, the resting, uncommitted lymphocytes that have not yet encountered antigen, were depleted in the high-risk groups. In their place, the researchers observed an expansion of activated B cells, plasmablasts and plasma cells, the antibody-secreting arm of the B lineage. This shift from a naive, quiescent pool toward a terminally differentiated, secretory population suggests that in patients prone to fibrosis, the humoral immune response remains locked in an activated state long after the acute viral challenge has passed.

Crucially, the different expanded subsets carried distinct functional imprints in their gene expression. Plasma cells from high-risk patients showed enrichment of transforming growth factor beta signaling, a pathway long implicated in driving fibroblasts to deposit scar-forming matrix, together with collagen metabolism and extracellular matrix remodeling programs. Plasmablasts, by contrast, were enriched for inflammasome-related genes, tumor necrosis factor signaling and angiogenesis pathways. In other words, the antibody-producing cells of high-risk patients were not merely numerous; they were transcriptionally wired toward the very biological processes, matrix deposition, inflammatory amplification and new blood vessel formation, that characterize the fibrotic niche in lung tissue.

The study also identified a potentially pathogenic B cell state marked by expression of FCRL5, an Fc receptor-like molecule associated with exhausted B cells. Elevated proportions of these FCRL5-positive exhausted B cells, alongside raised fractions of plasmablasts, were each statistically associated with increased mortality, as were reduced proportions of naive and memory B cells, with all of these associations reaching significance at p less than 0.05. The convergence of subset imbalance and survival outcome strengthens the argument that peripheral B cell architecture is not a passive bystander in post-COVID disease but a measurable correlate of clinical deterioration.

Clinically, the fibrosis risk stratification itself carried prognostic weight. Patients assigned to the high fibrosis risk group showed significantly worse short-term survival, with the difference reaching p less than 0.001. This means the grouping used to organize the transcriptomic analysis was not an arbitrary computational construct but a discriminator that separated patients by outcome. If the B cell features underlying that grouping can be reproduced in prospective cohorts, they could form the basis of a peripheral immune profiling strategy, a blood test capable of flagging which COVID-19 survivors warrant intensified radiological follow-up or early anti-fibrotic intervention.

The technical approach deserves attention in its own right. Integrating single-cell data across multiple cohorts is a nontrivial exercise, because datasets generated in different laboratories, on different platforms and from different patient populations carry systematic batch effects that can masquerade as biological signals. By requiring that B cell signatures replicate across independent public cohorts and an in-house post-discharge cohort with CT-confirmed outcomes, the authors mitigated the risk that their findings reflect artifacts of any single dataset. The two-week post-discharge sampling window in the Fujian cohort is particularly valuable, since it captures the immune system at a point where fibrotic processes are likely to be initiated but not yet fixed.

The findings also reframe the role of B cells in fibrotic disease more broadly. Pulmonary fibrosis research has traditionally centered on fibroblasts, macrophages and epithelial injury, with humoral immunity treated as peripheral to the scarring process. The observation that plasma cells in high-risk patients express coordinated TGF-beta, collagen and matrix remodeling programs suggests that antibody-secreting cells may participate directly in profibrotic signaling, or at minimum serve as circulating sentinels of fibrotic activity occurring in the lung. Either interpretation carries implications: the first points to B cell-directed therapies as potential antifibrotic strategies, while the second supports serial immune monitoring as a surrogate for disease activity.

The authors are careful to frame their results as identifying candidate biological processes rather than validated diagnostic markers. The associations were drawn largely from acute-phase samples stratified by estimated risk, and the post-discharge cohort, while clinically grounded, comprised only 13 patients. Prospective longitudinal studies will be needed to confirm whether B cell dysregulation precedes fibrosis development or accompanies it, and whether the signature retains predictive power in vaccinated populations and in the era of Omicron-lineage variants. Nevertheless, the study provides a concrete, mechanistically annotated set of peripheral immune features, depleted naive and memory B cells, expanded plasmablasts and plasma cells, and FCRL5-positive exhausted B cells, that can be tested directly. For the millions of COVID-19 survivors worldwide who live with uncertainty about their long-term lung health, a simple blood-based indicator of fibrosis risk would represent a meaningful step toward earlier detection and intervention.

Subject of Research: Peripheral B cell dysregulation associated with post-COVID-19 pulmonary fibrosis identified through multi-cohort single-cell RNA sequencing

Article Title: Peripheral B cell dysregulation associated with post-COVID-19 pulmonary fibrosis characterized by multi-cohort single-cell transcriptomics

Article References: Hang, W., Wu, S., Lin, H., Wu, Y., Zhong, W., Fang, J., Wu, J., He, Y., Xiao, Y., Ren, L., Xu, N., Lin, R., Zhou, Y., Li, H., & Li, H. (2026). Peripheral B cell dysregulation associated with post-COVID-19 pulmonary fibrosis characterized by multi-cohort single-cell transcriptomics. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08885-6

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08885-6

Keywords: post-COVID-19, pulmonary fibrosis, B cells, single-cell RNA sequencing, plasmablasts, plasma cells, TGF-beta signaling, extracellular matrix, immune biomarker, FCRL5, COVID-19, transcriptomics

The research team, led by scientists at Human Technopole in Milan, purified naive B cells, which have never encountered an antigen, and unswitched memory B cells, which carry the imprint of past infections, from the blood of healthy donors. They then activated both cell types in the laboratory using a cocktail that mimics T-cell-dependent stimulation: a cross-linker that engages the B cell receptor, multimeric CD40L to trigger the costimulatory CD40 receptor, and the cytokines IL-2 and IL-21. Over six days of culture, the researchers captured single-cell RNA sequencing and B cell receptor sequencing at four time points, from the resting state through the first cell division to full differentiation, retaining nearly 119,000 cells for analysis.

The first surprise came from comparing the two cell types at rest. At day zero, naive and memory B cells showed highly similar gene regulatory network activity, with a correlation of 0.89 across transcription factor regulons. Yet as activation progressed, the two populations drifted apart, and by day six the correlation had fallen to just 0.4. The transcriptional response to the very same stimulus was therefore profoundly cell-type-specific, with more than 3,000 genes differentially expressed between the two populations at the final time point.

That divergence translated into radically different fates. Memory B cells, when activated, almost exclusively differentiated into plasmablasts and plasma cells, the antibody factories of the immune system. Their gene expression was dominated by signatures of endoplasmic reticulum stress and the unfolded protein response, pathways such as IRE1α activating chaperones and XBP1(S) activating chaperone genes, which are hallmarks of cells ramping up massive antibody production. Naive B cells, by contrast, bifurcated. One branch produced plasma cells indistinguishable from those generated by memory cells, while the other adopted a germinal center phenotype marked by high expression of BCL6, CD81 and LIMK1, together with markers of memory precursors such as CCR6 and HHEX. An independent computational approach based on optimal transport, called Moscot, confirmed that germinal center cells arose almost exclusively from proliferating naive B cells, whereas plasmablasts could originate from either population.

The engine behind this fork in the road proved to be a pair of antagonistic transcription factors. The researchers applied the SCENIC framework to infer the activity of gene regulatory networks, or regulons, across the time course. They found that the activity of IRF4, the master driver of plasma cell differentiation, rose steadily in memory B cells from the earliest hours of activation and continued climbing throughout, culminating in expression of its downstream effector PRDM1. In naive B cells, IRF4 activity showed only a transient early increase before declining, persisting at high levels solely in the subset of cells that ultimately committed to the plasma cell fate. The activity of SPI1, also known as PU.1, behaved in exactly the opposite manner: strongly suppressed in memory cells, it rebounded in naive cells and peaked by day six, characterizing the germinal center state. Imaging flow cytometry revealed a mutually exclusive pattern of nuclear localization, with cells showing nuclear IRF4 consistently negative for nuclear PU.1 and vice versa, underscoring the antagonism between the two programs.

To test causality, the team deployed CRISPR-Cas9 to knock out IRF4 and PRDM1 in activated B cells, achieving knockout efficiencies of roughly 98 and 90 percent respectively. The consequences were dramatic. Loss of IRF4 blocked plasma cell differentiation in both naive and memory B cells and pushed the cells toward an aberrant germinal-center-like state that expressed canonical GC markers but differed transcriptionally from naturally arising germinal center cells by more than 2,600 genes. Knockout of PRDM1, in contrast, selectively eliminated plasma cells while preserving the capacity to form germinal center cells that were transcriptionally indistinguishable from those arising in control cultures. The conclusion is that PRDM1 is essential only for the plasma cell program, whereas IRF4 plays a dual and indispensable role, coordinating both plasma cell differentiation and proper germinal center development.

Perhaps the most conceptually striking finding concerns clonal behavior. By culturing only about 2,000 naive B cells and sequencing the entire culture at day six, the researchers identified 265 clones with at least ten cells each. A large proportion of these clones contained both plasma cells and germinal center cells, demonstrating that a single ancestral B cell can give rise to both fates. This rules out a simple population-level model in which different cells are pre-committed to different outcomes, and instead points to stochastic fluctuations in IRF4 expression within individual cells as the source of the bifurcation, particularly because the polyclonal stimulation system excludes any selection by antigen affinity.

The clonal analysis also revealed that gene expression itself is heritable. Sister cells within a clone showed significantly correlated expression of key plasma cell genes, including XBP1 and the immunoglobulin heavy chain gene IGHM, whereas random cell pairs from the same donor showed no such correlation. Genes regulated by XBP1 displayed especially strong intraclonal correlation, indicating that transcriptional programs central to the plasma cell lineage are inherited across cell divisions. To quantify this, the researchers trained three machine learning classifiers, logistic regression, a neural network and a random forest, to predict clonal identity from gene expression alone. Using a set of 369 genes with clonal correlation above 0.25, the logistic regression model correctly assigned sister cells with an average accuracy of nearly 88 percent, and the performance held up even after cell cycle and cell state effects were regressed out. Validation on eleven independent in vivo mouse B cell clonal datasets confirmed that the phenomenon is not an artifact of the culture system.

The study also shed light on antibody class switching, the process by which B cells replace the constant region of their antibody heavy chain to produce IgG, IgA or IgE while retaining antigen specificity. Using the sciCSR pipeline to quantify germline transcripts, the short non-coding RNAs that mark switch regions poised for recombination, the researchers found that more than 75 percent of germinal center cells expressed germline IGHG3, compared with only about 25 percent of plasma cells. Yet this priming did not translate into more switching, confirming that germline transcription is necessary but not sufficient for class switch recombination. Critically, by comparing IgM-positive cells from clones that contained switched cells with IgM-positive cells from entirely unswitched clones, the team found no transcriptional differences between the two groups. Belonging to a clonal lineage in which a sister cell has already switched therefore confers no increased predisposition to switch, providing direct experimental support for mathematical models proposing that class switching is a stochastic, cell-intrinsic event.

Together, these findings sketch a model in which each individual B cell is governed by a unique combination of competing gene programs that regulate cell state, clonal gene expression and isotype switching, maximizing the diversity of the immune response. Memory B cells carry an intrinsic bias toward plasma cell differentiation, driven by sustained IRF4 activity, yet they retain the latent capacity to adopt a germinal center fate when PRDM1 is suppressed, a discovery that could open new strategies for directing memory cells toward antibody refinement. Naive B cells, meanwhile, hedge their bets, with stochastic IRF4 dynamics splitting their progeny between immediate antibody secretion and the germinal center where future memory is made. As the authors note, gene regulatory network inference from single-cell transcriptomics remains inherently correlative, and future work with genome-wide transcription factor binding assays and high-throughput CRISPR screens will be needed to map the causal wiring in full. Even so, the study provides the most detailed picture yet of how human B cells decide their destinies, knowledge that is directly relevant to understanding responses to infection, vaccination and autoimmunity.

Subject of Research: Gene regulatory network dynamics controlling human naive and memory B cell differentiation and fate decisions

Article Title: Competing gene regulatory networks drive naive and memory B cell differentiation

Article References: Demela, P., Esposito, L., Marchesan, P., Nossa, L., Bolognini, D., Giacopuzzi, E., Ricciardelli, E., Ferrari, P., Bombelli, S., Peano, C., Prati, D., Valenti, L., & Soskic, B. (2026). Competing gene regulatory networks drive naive and memory B cell differentiation. Molecular Systems Biology, 22(7), 1097-1117. https://doi.org/10.1038/s44320-026-00207-8

Image Credits: AI Generated

DOI: 10.1038/s44320-026-00207-8

Keywords: B cells, gene regulatory networks, plasma cells, germinal center, IRF4, PRDM1, single-cell RNA sequencing, CRISPR, class switch recombination, clonal tracking, immune memory, transcription factors

The study, published in Nature Genetics, describes a clinically annotated, population-scale single-cell atlas built from bone marrow samples of 341 patients, spanning the full continuum of the disease from precursor conditions through newly diagnosed myeloma to relapsed and refractory disease after multiple lines of therapy. Using single-cell RNA sequencing enriched for plasma cells and the surrounding CD45-positive immune compartment, the researchers captured the transcriptomes of tens of thousands of individual cells, allowing them to dissect the malignant compartment cell by cell rather than averaging signals across bulk tumor tissue, which has historically masked the very heterogeneity that drives treatment failure.

Technically, the effort was formidable. Samples were processed using the MARS-seq platform and an updated version, MARS-seq2.0, with rigorous quality control on mitochondrial content, unique molecular identifier counts and detected genes. Cells were annotated through a computational pipeline combining scVI latent-space integration, uniform manifold approximation and projection embeddings, and inferCNV-based inference of copy number alterations to distinguish malignant plasma cells from their normal counterparts. The team then applied non-negative matrix factorization to decompose malignant gene expression into recurrent transcriptional programs, validated for stability through hundreds of bootstrapped iterations. This dual-layer analytical strategy allowed the investigators to separate two largely independent axes of tumor biology: what kind of myeloma a patient has, and how fast that myeloma is growing.

The first axis yielded five recurrent malignant transcriptional archetypes, designated MM1 through MM5, each corresponding to a stable pattern of gene expression anchored in distinct biological pathways. These archetypes align with known myeloma biology, including immunoglobulin heavy chain translocations such as t(11;14) with its cyclin D and BCL-2 dependencies, t(4;14) with NSD2 dysregulation, MAF and MAFB associated programs, and features reflecting unfolded protein response burden and bone marrow niche interactions. Crucially, the archetypes were not merely descriptive. They correlated with genomic features, therapeutic sensitivity patterns and clinical outcomes, and the team demonstrated that the classification could be ported to independent bulk RNA datasets, including the Blueprint cohort and the Multiple Myeloma Research Foundation’s CoMMpass cohort of treatment-naive patients, confirming that the single-cell-defined signatures retain prognostic power even when measured on standard clinical platforms.

The second axis, orthogonal to the archetypes, is a proliferative program. By scoring single-cell proliferation signatures and characterizing plasmablastic cells, the rapidly dividing precursors of antibody-secreting plasma cells, the researchers quantified the fraction of malignant cells actively cycling in each patient’s marrow. Proliferation has long been recognized as a poor prognostic marker in myeloma, measured historically by crude methods such as plasma cell labeling indices. The new work refines this concept at single-cell resolution, showing that the proportion of proliferating malignant plasma cells stratifies patients within every archetype, revealing intra-archetypal heterogeneity that earlier bulk approaches could not detect. In relapsed and refractory patients, higher proliferative fractions predicted shorter progression-free survival, and the effect persisted in multivariate Cox regression models adjusting for cytogenetic risk, age and prior treatment lines.

Combining the two axes produced an improved risk stratifier that outperformed existing molecular subtyping schemes. Patients could be placed into joint archetype-proliferation subgroups with meaningfully distinct progression-free and overall survival, and the framework added prognostic information beyond standard clinical variables including high-risk cytogenetics and chromosome 1p deletion. The validation in CoMMpass, one of the largest longitudinally followed myeloma cohorts in the world, demonstrated robustness and portability across sequencing platforms, an essential prerequisite for clinical translation. In principle, a myeloma patient’s tumor could one day be assigned to an archetype and proliferation state from a routine biopsy, guiding intensity of upfront therapy and informing decisions about transplantation, novel agents or early escalation.

Perhaps the most clinically electrifying result, however, came from the atlas’s use as a target-discovery engine. The team built a computational pipeline that ranked every protein-coding gene by a composite score integrating malignant enrichment, specificity for malignant plasma cells relative to normal plasma cells, and restriction across healthy tissues, the latter being critical to minimize off-tumor toxicity for any future immunotherapy. This screen surfaced FCRL2, an Fc receptor-like molecule with established roles in B cell biology, as a surface target expressed by malignant plasma cells but largely restricted to the B cell lineage elsewhere in the body. The atlas approach meant the researchers could verify not just that myeloma cells express FCRL2, but that expression is preserved across archetypes and proliferation states, addressing the antigen escape problem that plagues current myeloma immunotherapies.

The translational proof followed swiftly. The researchers engineered chimeric antigen receptor T cells directed against FCRL2 and tested them against myeloma cell lines with varying levels of target expression. In vitro, FCRL2-redirected CAR-T cells killed antigen-positive myeloma cells in an antigen-specific manner, with luciferase-based co-culture assays showing progressive suppression of tumor cell growth compared to non-transduced controls, and detailed immunophenotyping confirming proper CAR expression and memory-phenotype differentiation of the engineered cells. In mouse models, FCRL2-targeted CAR-T cells conferred a significant survival benefit. Given that existing myeloma immunotherapies targeting BCMA and GPRC5D eventually fail through antigen loss and relapse, a third lineage-restricted target backed by a genome-wide, single-cell-verified prioritization pipeline offers a credible path toward combination or sequential immunotherapy strategies.

For patients, the near-term significance is prognostic rather than therapeutic: an archetype and proliferation score could refine risk assessment well before relapse, when treatment decisions matter most. For the field, the study establishes a template for how population-scale single-cell atlases can move beyond description into actionable classification and target nomination. All of the underlying data, including the full scRNA-seq dataset deposited in the Gene Expression Omnibus and the analysis code released openly by the Amit lab, are publicly available, ensuring that other groups can interrogate, extend and challenge the framework. As single-cell sequencing costs fall and clinical grade assays mature, the line between research atlases and routine diagnostics grows thinner, and this myeloma atlas may be remembered as a turning point where that line was crossed for a historically intractable cancer.

Subject of Research: Single-cell transcriptomic atlas of multiple myeloma defining malignant archetypes, proliferative states, and the immunotherapy target FCRL2

Article Title: A single-cell atlas of multiple myeloma defines malignant archetypes and proliferative states

Article References: Zada, M., Kurilovich, A., Shapira, N., Wang, S.-Y., Sharet-Eshed, R., Kfir-Erenfeld, S., Schlossberg, M., Zorde, E., Asherie, N., Gur, C., Chalan, P., Shalita, R., Ben Yehuda, M., Zwicky, P., von Locquenghien, M., Ingelfinger, F., Mazuz, K., David, E., Gurevich-Shapiro, A., … Amit, I. (2026). A single-cell atlas of multiple myeloma defines malignant archetypes and proliferative states. Nature Genetics, 58(9), 2254-2269. https://doi.org/10.1038/s41588-026-02725-5

Image Credits: AI Generated

DOI: 10.1038/s41588-026-02725-5

Keywords: multiple myeloma, single-cell RNA sequencing, transcriptional archetypes, proliferation, FCRL2, CAR-T cell therapy, risk stratification, plasma cells, Nature Genetics, precision medicine, CoMMpass cohort, target discovery